Focal Cortical Dysplasia, Hemimegalencephaly, Tuberous Sclerosis Complex (TSC)
Conditions
Keywords
FCD-II, TSC, HME
Brief summary
This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME.
Detailed description
This is an open-label, phase 1b/2a study to evaluate safety, tolerability, and pharmacokinetics SVG103 (paxalisib) in 12 patients with Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME). The name of the study drug involved in this study is SVG103 (paxalisib). The trial consists of a 4 week prospective baseline period (D-28\ D1) to collect seizure data, followed by a 12-week treatment phase. And, there is a 4-week washout (follow-up) phase. It is expected that about 12 participants will take part in this research study for up to 3-4 months as long as there is no serious side effects and disease progression. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved SVG103 (paxalisib) for this specific disease.
Interventions
DRUGSVG103
The study treatment is administered for 3 months during the core phase and for an additional 6 months during the extension phase. Oral, daily, dosage per protocol.
Sponsors
Sovargen
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Participants diagnosed with: * FCD-II: diagnosis of FCD Type II based on clinical symptoms and confirmed by a positive magnetic resonance imaging (MRI) or histological/pathological analysis of brain tissue, or * TSC: diagnosis of TSC by either clinical or genetic diagnostic criteria as documented in the participant's medical record, or * HME: Definitive HME confirmed with MRI. 2. Male or female between the ages of 18 and 65 years of age (inclusive). 3. History of failure to control seizures despite at least 2 ASMs at appropriate dosages and duration of treatment. 4. Participants must have experienced at least 8 countable seizures per month for 2 of the 3 months as documented in historical seizure diaries before the baseline period. 6\. If participants are on a ketogenic or modified atkins diet, that the regimen can remain unchanged throughout the study, in the opinion of the investigator. 7\. Participants with Neurostimulation devices (i.e. Vagus Nerve Stimulation (VNS), Responsive Neuro Stimulation (RNS), Deep Brain Stimulation (DBS) who meet all of the following conditions: * The device has been implanted for ≥1 year prior to the screening visit. * The settings must have remained constant for 3 months prior to the screening visit and can remain constant throughout the study, in the opinion of the investigator. * The battery is expected to last throughout the study. 8. A participant/caregiver or LAR willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures. Key
Exclusion criteria
1. Clinically significant hepatic, renal, pulmonary, gastrointestinal, neurological (other than epilepsy; HME; TSC; FCD-II), autoimmune, immunological, infections, hematological, malignant conditions that may interfere with or impact the participation in the study or study conduct, as determined but the investigator or sponsor. 2. Immunocompromised participants, defined as acquired immune deficiency syndrome (AIDS), cancer, malnutrition, and certain genetic disorders or undergoing treatment with anticancer drugs, radiation therapy, and stem cell or organ transplant. 3. Participants who have an active central nervous system (CNS) infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive as evaluated by brain imaging (magnetic resonance imaging \[MRI\]). 4. Participants being considered for brain surgery during the study or has undergone brain surgery within 6 months prior to screening visit for epilepsy or any other reason. 5. Participants with HbA1c levels ≥9.0%, or with hyperglycemia or diabetes requiring insulin therapy, or significant uncontrolled hyperglycaemia or diabetes mellitus that would compromise patient safety, as determined by the investigator. 6. Participants with active pneumonitis that are clinically symptomatic. 7. Participants with a history of myocardial infarction or coronary artery disease or clinically significant ECG abnormality. 8. Participants who have clinically significant hepatic, renal and blood laboratory values at baseline period. 9. Participants with known sensitivity or allergy to any component in the investigational product(s) (microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Adverse Drug Reactions (ADRs), TEAEs Leading to Discontinuation and Severity of TEAEs | Up to 12 Weeks | An adverse event (AE) was any untoward medical occurrence in a clinical study patient, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event was any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or any other event that requires scientific judgment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in seizure frequency | Baseline (week 1) to week 12 | Assessed by seizure diaries |
Countries
Australia
Outcome results
None listed